BioSpace

BMS’ Phase 3 win for lung drug clouded by high-dose miss

A low-dose win could derisk a regulatory pathway for BMS’ LPA1 antagonist in idiopathic pulmonary fibrosis after a recently reported patient death, but a miss at the higher dose leaves analysts awaiting full data.

By BioSpace

1 min read
BMS’ Phase 3 win for lung drug clouded by high-dose miss
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights